Tags: icahn | amylin | drug | pharma

Icahn Drops Amylin Suit After Talks With CEO

Wednesday, 25 Apr 2012 04:17 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink
Billionaire Carl Icahn dropped a lawsuit against Amylin Pharmaceuticals Inc. over a corporate bylaw that blocked investors from ousting directors who rejected a Bristol-Myers Squibb Co. takeover offer.

Icahn, Amylin’s third-largest investor, withdrew the complaint after meeting with Amylin Chief Executive Officer Daniel Bradbury, Icahn said Wednesday in an e-mailed statement. Icahn, who criticized Amylin officials for rejecting the $22-a- share bid, didn’t disclose the subject of the talks.

“I continue to strongly believe this company should be sold at this time,” Icahn said in a telephone interview. “It would be a great acquisition for a number of big pharma companies.”

Icahn, who has threatened proxy fights against at least seven drug companies in the past five years, sued Amylin in Delaware Chancery Court over a rule requiring advance notice of candidates for board seats after the board rejected Bristol- Myers’s $3.5 billion buyout bid.

A separate Icahn suit pending in state court in Delaware seeks records about Amylin’s consideration of the offer.

Officials of San Diego-based Amylin, make of the diabetes drugs Bydureon and Byetta, said they were pleased with Icahn’s decision to drop the bylaw suit.

‘Greatest Value’

The company’s board “continually considers all options available and is relentlessly focused on creating the greatest value for our stockholders,” Alice Izzo, an Amylin spokeswoman, said in an e-mailed statement.

Amylin rose 2.9 percent to $26.28 at 3:32 p.m. New York time in Nasdaq Stock Market trading. BeforeWednesday, the shares had gained 66 percent since March 27, the day before the Bristol-Myers bid was reported.

Icahn, who held 14.4 million Amylin shares as of April 4, gained board representation in 2009 after running a proxy contest in which he criticized the company’s ability to return value to shareholders.

In the bylaw suit, Icahn alleged that Amylin officials set a Jan. 25 cutoff for submitting names of potential candidates for company board seats. The deadline expired before the disclosure of the Bristol-Myers offer, the billionaire said.

The case was Icahn Partners LP v. Amylin Pharmaceuticals Inc., CA 7404, Delaware Chancery Court (Wilmington).

© Copyright 2014 Bloomberg News. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web

Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Retype Email:
Country
Zip Code:
Privacy: We never share your email.
 

You May Also Like
Around the Web

Most Commented

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved